{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:21:05Z","timestamp":1779142865469,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In inflamed tissue, immune cells are accumulated, and various intercellular signals are involved in the pathogenesis. Janus kinases (JAKs) are typical tyrosine kinases involved in mediating the signaling of multiple cytokines and growth factors and induce the transcription of molecules related to inflammation or immunity via the transcription factor signal transducers and activators of transcription (STAT). Hence, they have garnered significant interest as a therapeutic target. JAK inhibitors have been evaluated as a major drug for remission induction in the treatment of autoimmune diseases such as rheumatoid arthritis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Body<\/jats:title>\n                <jats:p>Covid-19 infection due to SARS-CoV-2 has caused a pandemic, with approximately 660 million infections and 6.7 million deaths worldwide\u00a0(January, 2023). The prognosis is poor and the major causes of death are respiratory failure attributed to rapid pneumonia, thromboembolism due to a cytokine storm, and multi-organ failure. As a treatment modality, molecular targeted therapy, such as cytokine-targeting therapy, is attracting attention, in addition to antiviral drugs. Baricitinib, a JAK inhibitor, is used for the treatment of severe pneumonia, in addition to antiviral drugs and glucocorticoids. The mechanism of action of baricitinib includes inhibition of viral receptor-mediated endocytosis, which involves the NF-\u03baB activating kinase (NAK) family, and mediating the anti-cytokine effects via JAK 1\/2 inhibition. It improves severe pneumonia and reduces mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Thus, the development of molecular targeted drugs with elucidated pathological mechanisms may aid in controlling Covid-19 infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41232-022-00253-3","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T04:11:02Z","timestamp":1673237462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia"],"prefix":"10.1186","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"253_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020;395:497\u2013506.","journal-title":"China. Lancet"},{"key":"253_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0140-6736(20)31278-2","volume":"396","author":"Z Li","year":"2020","unstructured":"Li Z, Chen Q, Feng L, Rodewald L, et al. Active case finding with case management: the key to tackling the COVID-19 pandemic. Lancet. 2020;396:63\u201370.","journal-title":"Lancet."},{"key":"253_CR3","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1016\/S0140-6736(22)00008-3","volume":"399","author":"LS Flor","year":"2022","unstructured":"Flor LS, Friedman J, Spencer CN, et al. Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021. Lancet. 2022;399:2381\u201397.","journal-title":"Lancet"},{"key":"253_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(21)02346-1","volume":"399","author":"RW Peeling","year":"2022","unstructured":"Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022;399:757\u201368.","journal-title":"Lancet."},{"key":"253_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","volume":"603","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Bastard P, Human Genetic Effort COVID, Cobat A, Casanova JL. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603:587\u201398.","journal-title":"Nature."},{"key":"253_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1126\/science.abm8108","volume":"375","author":"M Merad","year":"2022","unstructured":"Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122\u20137.","journal-title":"Science."},{"issue":"11","key":"253_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra2206573","volume":"387","author":"DH Barouch","year":"2022","unstructured":"Barouch DH. Covid-19 Vaccines - Immunity, Variants, Boosters. N Engl J Med. 2022;387(11):1011\u201320. https:\/\/doi.org\/10.1056\/NEJMra2206573.","journal-title":"N Engl J Med"},{"key":"253_CR8","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMcp2009249","volume":"383","author":"RT Gandhi","year":"2020","unstructured":"Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020;383:1757\u201366.","journal-title":"N Engl J Med."},{"key":"253_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1056\/NEJMe2118579","volume":"386","author":"EL Heil","year":"2022","unstructured":"Heil EL, Kottilil S. The Goldilocks Time for Remdesivir - Is Any Indication Just Right? N Engl J Med. 2022;386:385\u20137.","journal-title":"N Engl J Med."},{"key":"253_CR10","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","volume":"383","author":"DA Berlin","year":"2020","unstructured":"Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383:2451\u201360.","journal-title":"N Engl J Med."},{"key":"253_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11010-021-04325-9","volume":"477","author":"F Rommasi","year":"2022","unstructured":"Rommasi F, Nasiri MJ, Mirsaeidi M. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features. Mol Cell Biochem. 2022;477:711\u201326.","journal-title":"Mol Cell Biochem."},{"key":"253_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","volume":"28","author":"FL van de Veerdonk","year":"2022","unstructured":"van de Veerdonk FL, Giamarellos-Bourboulis E, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28:39\u201350.","journal-title":"Nat Med."},{"key":"253_CR13","doi-asserted-by":"publisher","first-page":"e12697","DOI":"10.15252\/emmm.202012697","volume":"12","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12:e12697.","journal-title":"EMBO Mol Med"},{"key":"253_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al. ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384:795\u2013807.","journal-title":"N Engl J Med."},{"issue":"9","key":"253_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMe2034982","volume":"384","author":"D Goletti","year":"2021","unstructured":"Goletti D, Cantini F. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled. N Engl J Med. 2021;384(9):867\u20139.","journal-title":"N Engl J Med."},{"key":"253_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","volume":"377","author":"P Macchi","year":"1005","unstructured":"Macchi P, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1005;377:65\u20138.","journal-title":"Nature"},{"key":"253_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2012","unstructured":"O'Shea JJ, et al. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2012;368:161\u201370.","journal-title":"N Engl J Med"},{"key":"253_CR18","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O'Shea","year":"2013","unstructured":"O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72:ii111\u20135.","journal-title":"Ann Rheum Dis"},{"key":"253_CR19","doi-asserted-by":"publisher","first-page":"i70","DOI":"10.1136\/annrheumdis-2011-200595","volume":"71","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Maeshima Y, Yamaoaka K. In vitro and in vivo analysis of a Jak inhibitor in rheumatoid arthritis. Ann Rheum Dis. 2012;71:i70\u20134.","journal-title":"Ann Rheum Dis"},{"key":"253_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12 month data from a 24 month Phase 3 randomized radiographic study. Arthritis Rheumatol. 2013;65:559\u201370.","journal-title":"Arthritis Rheumatol"},{"key":"253_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea J, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"253_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s41232-020-00133-8","volume":"40","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. Rheumatoid arthritis. Inflamm Regen. 2020;40:20. https:\/\/doi.org\/10.1186\/s41232-020-00133-8.","journal-title":"Rheumatoid arthritis. Inflamm Regen."},{"issue":"4","key":"253_CR23","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"8","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;8(4):18001.","journal-title":"Nat Rev Dis Primers"},{"key":"253_CR24","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328\u201337.","journal-title":"Lancet."},{"key":"253_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376:652\u201362.","journal-title":"N Engl J Med."},{"key":"253_CR26","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"253_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383:1813\u201326.","journal-title":"N Engl J Med."},{"key":"253_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/1756-185X.14124","volume":"24","author":"LS Tam","year":"2021","unstructured":"Tam LS, Tanaka Y, Handa R, et al. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. Int J Rheum Dis. 2021;24:733\u201345.","journal-title":"Int J Rheum Dis"},{"key":"253_CR29","doi-asserted-by":"publisher","first-page":"102666","DOI":"10.1016\/j.autrev.2020.102666","volume":"19","author":"E De Lorenzis","year":"2020","unstructured":"De Lorenzis E, Natalello G, Gigante L, et al. What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19? Autoimmun Rev. 2020;19:102666.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"253_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","volume":"30","author":"M Tardella","year":"2022","unstructured":"Tardella M, Di Carlo M, Carotti M, et al. A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacology. 2022 Jun;30(3):705\u201312.","journal-title":"Inflammopharmacology."},{"key":"253_CR31","doi-asserted-by":"publisher","first-page":"e22336","DOI":"10.1096\/fj.202101436R","volume":"36","author":"S Wang","year":"2022","unstructured":"Wang S, Liu M, Li X, et al. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. FASEB J. 2022;36:e22336.","journal-title":"FASEB J"},{"key":"253_CR32","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"COV-BARRIER Study Group, Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9:1407\u201318.","journal-title":"Lancet Respir Med"},{"key":"253_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","volume":"10","author":"EW Ely","year":"2022","unstructured":"COV-BARRIER Study Group, Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327\u201336.","journal-title":"Lancet Respir Med"},{"key":"253_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","volume":"400","author":"RECOVERY Collaborative Group","year":"2022","unstructured":"RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359\u201368.","journal-title":"Lancet"},{"key":"253_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41375-020-01087-z","volume":"35","author":"A D'Alessio","year":"2021","unstructured":"D'Alessio A, Del Poggio P, Bracchi F, et al. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. Leukemia. 2021;35:635\u20138.","journal-title":"Leukemia."},{"key":"253_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"PO Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es PO, Quirk D, Furtado RH, et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;385:406\u201315.","journal-title":"N Engl J Med"},{"key":"253_CR37","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"REMAP-CAP Investigators","year":"2021","unstructured":"Investigators REMAP-CAP, Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384:1491\u2013502.","journal-title":"N Engl J Med."}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-022-00253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-022-00253-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-022-00253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T07:14:38Z","timestamp":1673507678000},"score":1,"resource":{"primary":{"URL":"https:\/\/inflammregen.biomedcentral.com\/articles\/10.1186\/s41232-022-00253-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["253"],"URL":"https:\/\/doi.org\/10.1186\/s41232-022-00253-3","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"8 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y. Tanaka has received speaking fees and\/or honoraria from Behringer-Ingelheim, Eli Lilly, Abbvie, Gilead, AstraZeneca, Bristol-Myers, Chugai, Daiichi-Sankyo, Eisai, Pfizer, Mitsubishi-Tanabe, GlaxoSmithKline, received research grants from Asahi-Kasei, Abbvie, Chugai, Eisai, Takeda, Daiichi-Sankyo, Behringer-Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}